Your browser doesn't support javascript.
loading
Bratislava Statement: consensus recommendations for improving pancreatic cancer care.
Prades, Joan; Arnold, Dirk; Brunner, Thomas; Cardone, Antonella; Carrato, Alfredo; Coll-Ortega, Cristina; De Luze, Samuel; Garel, Pascal; Goossens, Maria E; Grilli, Roberto; Harris, Meggan; Louagie, Marleen; Malats, Núria; Minicozzi, Pamela; Partelli, Stefano; Pastorekova, Silvia; Petrulionis, Marius; Price, Richard; Sclafani, Francesco; Smolkova, Bozena; Borras, Josep M.
Afiliación
  • Prades J; Catalonian Cancer Strategy, Department of Health, Barcelona, Spain; University of Barcelona (IDIBELL), Barcelona, Spain. Electronic address: jlprades@iconcologia.net.
  • Arnold D; Med. Onkologie, Tumorzentrum Hamburg, AK Altona, Hamburg, Germany; European Society of Medical Oncology (ESMO), Lugano, Ticino, Switzerland.
  • Brunner T; Department of Radiation Oncology, University of Magdeburg, Magdeburg, Germany; European Society for Radiotherapy & Oncology (ESTRO), Brussels, Belgium.
  • Cardone A; Pancreatic Cancer Europe, Brussels, Belgium; European Cancer Patient Coalition (ECPC), Brussels, Belgium.
  • Carrato A; Pancreatic Cancer Europe, Brussels, Belgium; IRYCIS, CIBERONIC, Madrid, Spain.
  • Coll-Ortega C; Catalonian Cancer Strategy, Department of Health, Barcelona, Spain.
  • De Luze S; Institut National du Cancer, Billancourt, Île-de-France, France.
  • Garel P; European Hospital and Healthcare Federation, Brussels, Belgium.
  • Goossens ME; Cancer Centre-OD Public Health and Surveillance, Sciensano, Brussels, Belgium.
  • Grilli R; Azienda USL-IRCCS of Reggio Emilia, Bologna, Italy.
  • Harris M; Independent Researcher, Valencia, Spain.
  • Louagie M; Belgian National Institute for Health and Disability Insurance, Brussels, Belgium.
  • Malats N; Pancreatic Cancer Europe, Brussels, Belgium; Spanish National Cancer Research Centre (CNIO), CIBERONC, Madrid, Spain.
  • Minicozzi P; London School of Hygiene & Tropical Medicine, London, UK; Analytical Epidemiology and Health Impact Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Partelli S; Università Vita Salute San Raffaele, Milano, Lombardia, Italy; European Society of Surgical Oncology (ESSO), Brussels, Belgium.
  • Pastorekova S; Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Petrulionis M; Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania; Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Price R; The European Cancer Organisation (ECCO), Brussels, Belgium.
  • Sclafani F; Department of Medical Oncology, Institut Jules Bordet, Bruxelles, Belgium; European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
  • Smolkova B; Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
  • Borras JM; Catalonian Cancer Strategy, Department of Health, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalunya, Spain.
ESMO Open ; 5(6): e001051, 2020 11.
Article en En | MEDLINE | ID: mdl-33188052
Pancreatic cancer is one of the most lethal tumours, and it is the fourth cause of cancer death in Europe. Despite its important public health impact, no effective treatments exist, nor are there high-visibility research efforts to improve care. This alarming situation is emblematic of a larger group of cancer diseases, known as neglected cancers. To address the impact of these diseases, the European Commission-supported Innovative Partnership for Action Against Cancer launched a multi-stakeholder initiative to determine key steps that healthcare systems can rapidly implement to improve their response. A working group comprising 20 representatives from European medical societies, patient associations, cancer plan organisations and other relevant European healthcare stakeholders was organised. A consensus process based on the results of different studies, discussion of research outcomes, and development and endorsement of draft statements resulted in 22 consensus recommendations (the Bratislava Statement). The statement argues that substantial improvements can be achieved in patient outcomes by centralising pancreatic cancer care around state-of-the-art reference centres, staffed by expert multidisciplinary teams capable of providing high-quality care. This organisational model requires a specific care framework encompassing primary, palliative and survivorship care, and a policy environment prioritising the use of quality criteria and performance assessments as well as research investments dedicated to prevention, risk prediction, early detection and diagnosis. In order to address the challenges posed by neglected cancers in general and pancreatic cancer in particular, a specific control strategy tailored to this reality is required.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Calidad de la Atención de Salud Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Calidad de la Atención de Salud Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: ESMO Open Año: 2020 Tipo del documento: Article Pais de publicación: Reino Unido